TScan Therapeutics (TCRX) Interest & Investment Income (2020 - 2026)
TScan Therapeutics (TCRX) posted quarterly Interest & Investment Income of $1.2 million for Q1 2026, up 2212.73% year-over-year from $50243.7 in Q1 2025, and up 115.95% quarter-over-quarter from -$7.3 million in Q4 2025.
TScan Therapeutics (TCRX) Interest & Investment Income (2020 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Interest & Investment Income for 7 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 2212.73% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at -$1.7 million (up 22.93% YoY), while the FY2025 annual figure was -$51000.0, down 200.0% from the prior year.
- Interest & Investment Income improved to $1.2 million in Q1 2026 per TCRX's latest filing, from -$7.3 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $3.7 million in Q3 2024 and bottomed at -$9.2 million in Q4 2024.
- Historically, Interest & Investment Income has averaged $464411.8 across 5 years, with a median of $1.2 million in 2026.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 44950.0% — and 2024, when it tumbled 455.82%.
- TScan Therapeutics' Interest & Investment Income stood at $901000.0 in 2022, then soared by 188.12% to $2.6 million in 2023, then sank by 455.82% to -$9.2 million in 2024, then climbed by 21.14% to -$7.3 million in 2025, then soared by 115.95% to $1.2 million in 2026.
- Business Quant data shows TCRX's Interest & Investment Income at $1.2 million in Q1 2026, -$7.3 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 833,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 833,000.00 |
| Mar 31, 2026 | 1.16 Mn |
| Dec 31, 2025 | -7.28 Mn |
| Sep 30, 2025 | 2.04 Mn |
| Jun 30, 2025 | 2.39 Mn |
| Mar 31, 2025 | -55,000.00 |
| Dec 31, 2024 | -9.24 Mn |
| Sep 30, 2024 | 3.69 Mn |
| Jun 30, 2024 | 3.41 Mn |
| Mar 31, 2024 | 2.19 Mn |
| Dec 31, 2023 | 2.60 Mn |
| Sep 30, 2023 | 2.73 Mn |
| Jun 30, 2023 | 1.53 Mn |
| Mar 31, 2023 | 1.14 Mn |
| Dec 31, 2022 | 901,000.00 |
| Sep 30, 2022 | 534,000.00 |
| Jun 30, 2022 | 149,000.00 |
| Mar 31, 2022 | 7,000.00 |
| Dec 31, 2021 | 2,000.00 |
| Sep 30, 2021 | 3,000.00 |